Takeda Pharmaceutical, Galaxy Biotech to Sign Licensing Agreement for HuL2G7, Investigational Agent for Cancer Treatment.Tokyo, Japan, July 12, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical has signed a licensing agreement with Galaxy Biotech for HuL2G7, an anti-Hepatocyte Growth Factor (HGF HGF, n See glucagon. ) monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing developed by Galaxy Biotech. Under the agreement announced July 10, Takeda Pharmaceutical will licensed to exclusively develop, manufacture, and sell HuL2G7 worldwide. Takeda Pharmaceutical will make an upfront payment of $2 million, milestone payments on future development and royalties on product sales. In addition, Takeda Pharmaceutical will provide Galaxy Biotech with millions of dollars for R&D over the next four years. HuL2G7 is a humanized monoclonal antibody that inhibits the activities of HGF. It is reported that HGF is involved in tumor tumor: see neoplasm. stasis stasis /sta·sis/ (sta´sis) 1. a stoppage or diminution of flow, as of blood or other body fluid. 2. a state of equilibrium among opposing forces. and growth, antiapoptosis and neoangiogenesis. In the recent studies, HuL2G7 has demonstrated an effect to promote tumor regression and improve survival. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion